Recent trends in the U.S. compounding pharmacies market are driven by an increase in the number of regulatory initiatives. Considering an instance, in April 2020, the U.S. FDA permitted some smaller compounders to make certain drugs for the treatment of patients on ventilators amid the COVID-19 pandemic. The move came after the regulator allowed registered outsourcing facilities to compound similar drugs against the surging demand and shortages during the crisis.

The policy was applicable to federal facilities and state-licensed pharmacies, that were regulated under Section 503A of the Federal Food, Drug, and Cosmetics Act. Unlike outsourcing facilities, these did not have to comply with the requirements of the current good manufacturing practice (cGMP).

Such compounding pharmacy regulations are slated to push industry demand through the forecasted period. On this note, the U.S. compounding pharmacies market size is anticipated to surpass USD 7.2 billion by 2027, cites the latest research by Global Market Insights, Inc. 

Request for a sample copy of this report @

Prominent participants in the U.S. compounding pharmacies market include Fresenius Kabi,  Dougherty’s Pharmacy, Athenex Pharma Solutions, B. Braun, McGuff Company, Institutional Pharmacy Solutions, and Fagron, amongst others.

These players are focusing on numerous growth strategies for securing financial stability and enhancing their product penetration. For instance, in January 2015, Dougherty Holdings proceeded with the acquisition of McCrory’s Pharmacy in El Paso. The takeover boosted the sales of the firm.

Some major trends augmenting U.S. compounding pharmacies industry growth comprise:

Increasing demand for rectal administration

Rectal administration is less costly and is usually preferred when the oral route is not permitted. These dose forms provide a considerable placebo effect over the treatment of anorectal illnesses.

The rectal segment in the U.S. compounding pharmacies market accounted for 8.5 per cent of the overall valuation in 2020. The segment is fragmented into enema, suppositories, and others.

Surging preference for 503B pharmacies

The 503B pharmacy type segment in the U.S. compounding pharmacies industry is expected to exhibit an appreciable CAGR of 8 per cent through 2027. This growth is mainly attributed to the large scale production of compounded medications that bring about a reduction in the costs of manufacturing.

Moreover, these pharmacies also provide numerous solutions that are safe and effective for assisting customers at healthcare facilities. Thus, various advantages associated with the 503B compounding pharmacy type are set to foster segmental expansion over the assessment span.

Rising adoption in veterinary care

Compounding pharmacy injectables are useful in providing treatment to animals when there is an absence of government-approved medications. The veterinary segment is projected to depict a substantial CAGR of over 4.5 per cent through 2027.

The doses of commercially available medicines are legalized for deployment in few species but are not preferred to be administered in other species comprising cats and other exotic animals. The profitability of a compounding pharmacy is that, in such instances, it provides specifically formulated drugs for animal species.

In a nutshell, the increasing shortage of various drugs comprising cancer medications and emergency drugs is expected to drive U.S. compounding pharmacies industry expansion over the analysis period.

Browse full table of contents (TOC) of this report @

Partial Chapter of the Table of Content 

Chapter 4   US Compounding Pharmacies Market, By Pharmacy Type

4.1    Key segment trends

4.2    503A

4.2.1    503A market, by country, 2016 - 2027, (USD Million)

4.3    503B

4.3.1    503B market, by country, 2016 - 2027, (USD Million)

Chapter 5   US Compounding Pharmacies Market, By Sterility

5.1    Key segment trends

5.2    Sterile

5.2.1    Sterile market, by country, 2016 - 2027, (USD Million)

5.3    Non-sterile

5.3.1    Non-sterile market, by country, 2016 - 2027, (USD Million)